nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—bone cancer—skin cancer	0.186	0.39	CtDrD
Methotrexate—germ cell cancer—skin cancer	0.148	0.309	CtDrD
Methotrexate—psoriasis—skin cancer	0.144	0.301	CtDrD
Methotrexate—PGD—Dacarbazine—skin cancer	0.0755	0.206	CbGbCtD
Methotrexate—MTHFR—Fluorouracil—skin cancer	0.0362	0.0989	CbGbCtD
Methotrexate—TYMS—Fluorouracil—skin cancer	0.0308	0.0842	CbGbCtD
Methotrexate—ABCC1—Vemurafenib—skin cancer	0.0219	0.0597	CbGbCtD
Methotrexate—ABCC10—Docetaxel—skin cancer	0.0194	0.053	CbGbCtD
Methotrexate—ABCG2—Vismodegib—skin cancer	0.0185	0.0505	CbGbCtD
Methotrexate—ABCC3—Fluorouracil—skin cancer	0.016	0.0437	CbGbCtD
Methotrexate—ABCG2—Vemurafenib—skin cancer	0.0146	0.0399	CbGbCtD
Methotrexate—ABCC1—Dactinomycin—skin cancer	0.0145	0.0396	CbGbCtD
Methotrexate—ALB—Vismodegib—skin cancer	0.0128	0.0348	CbGbCtD
Methotrexate—SLC22A7—Fluorouracil—skin cancer	0.0125	0.0341	CbGbCtD
Methotrexate—ABCC4—Fluorouracil—skin cancer	0.0122	0.0334	CbGbCtD
Methotrexate—SLCO1B3—Docetaxel—skin cancer	0.0108	0.0296	CbGbCtD
Methotrexate—ALB—Vemurafenib—skin cancer	0.0101	0.0275	CbGbCtD
Methotrexate—ABCG2—Dactinomycin—skin cancer	0.00972	0.0265	CbGbCtD
Methotrexate—SLC22A7—Docetaxel—skin cancer	0.00955	0.0261	CbGbCtD
Methotrexate—ABCC1—Docetaxel—skin cancer	0.0075	0.0205	CbGbCtD
Methotrexate—ABCB1—Vismodegib—skin cancer	0.00667	0.0182	CbGbCtD
Methotrexate—ABCG2—Fluorouracil—skin cancer	0.00657	0.0179	CbGbCtD
Methotrexate—ABCC2—Docetaxel—skin cancer	0.00555	0.0152	CbGbCtD
Methotrexate—ABCG2—Docetaxel—skin cancer	0.00502	0.0137	CbGbCtD
Methotrexate—ALB—Fluorouracil—skin cancer	0.00453	0.0124	CbGbCtD
Methotrexate—ATIC—pes—skin cancer	0.00406	0.0903	CbGeAlD
Methotrexate—ABCB1—Dactinomycin—skin cancer	0.0035	0.00957	CbGbCtD
Methotrexate—ATIC—leg—skin cancer	0.00207	0.046	CbGeAlD
Methotrexate—ATIC—forelimb—skin cancer	0.00205	0.0457	CbGeAlD
Methotrexate—ATIC—hindlimb—skin cancer	0.00185	0.0411	CbGeAlD
Methotrexate—ABCB1—Docetaxel—skin cancer	0.00181	0.00494	CbGbCtD
Methotrexate—ATIC—appendage—skin cancer	0.00159	0.0353	CbGeAlD
Methotrexate—ATIC—skin epidermis—skin cancer	0.00132	0.0293	CbGeAlD
Methotrexate—FOLR1—nipple—skin cancer	0.00113	0.0251	CbGeAlD
Methotrexate—GGH—hair follicle—skin cancer	0.00111	0.0246	CbGeAlD
Methotrexate—FOLR1—epithelium—skin cancer	0.00076	0.0169	CbGeAlD
Methotrexate—GGH—nipple—skin cancer	0.000751	0.0167	CbGeAlD
Methotrexate—TYMS—Sorafenib—Vismodegib—skin cancer	0.000709	0.584	CbGdCrCtD
Methotrexate—SLCO4C1—nipple—skin cancer	0.000666	0.0148	CbGeAlD
Methotrexate—FPGS—nipple—skin cancer	0.00066	0.0147	CbGeAlD
Methotrexate—MTHFR—blood vessel—skin cancer	0.000656	0.0146	CbGeAlD
Methotrexate—FOLR1—lymphoid tissue—skin cancer	0.000586	0.013	CbGeAlD
Methotrexate—FOLR1—female reproductive system—skin cancer	0.000565	0.0126	CbGeAlD
Methotrexate—ABCC11—female reproductive system—skin cancer	0.000542	0.012	CbGeAlD
Methotrexate—SLC19A1—lymphoid tissue—skin cancer	0.000514	0.0114	CbGeAlD
Methotrexate—TYMS—Paclitaxel—Docetaxel—skin cancer	0.000505	0.416	CbGdCrCtD
Methotrexate—SLC19A1—female reproductive system—skin cancer	0.000495	0.011	CbGeAlD
Methotrexate—GGH—skin of body—skin cancer	0.000481	0.0107	CbGeAlD
Methotrexate—FOLR1—head—skin cancer	0.000472	0.0105	CbGeAlD
Methotrexate—MTHFR—neck—skin cancer	0.000469	0.0104	CbGeAlD
Methotrexate—FPGS—connective tissue—skin cancer	0.000468	0.0104	CbGeAlD
Methotrexate—SLCO3A1—nipple—skin cancer	0.000467	0.0104	CbGeAlD
Methotrexate—ATIC—connective tissue—skin cancer	0.000453	0.0101	CbGeAlD
Methotrexate—GGH—mammalian vulva—skin cancer	0.000438	0.00974	CbGeAlD
Methotrexate—ATIC—epithelium—skin cancer	0.00043	0.00955	CbGeAlD
Methotrexate—DHFR—nipple—skin cancer	0.000429	0.00953	CbGeAlD
Methotrexate—FPGS—skin of body—skin cancer	0.000423	0.00939	CbGeAlD
Methotrexate—SLC19A1—head—skin cancer	0.000414	0.0092	CbGeAlD
Methotrexate—PGD—nipple—skin cancer	0.000412	0.00916	CbGeAlD
Methotrexate—ATIC—skin of body—skin cancer	0.000409	0.00909	CbGeAlD
Methotrexate—PGD—neck—skin cancer	0.000408	0.00906	CbGeAlD
Methotrexate—SLC46A1—lymphoid tissue—skin cancer	0.000396	0.00879	CbGeAlD
Methotrexate—SLCO4C1—mammalian vulva—skin cancer	0.000389	0.00864	CbGeAlD
Methotrexate—FPGS—mammalian vulva—skin cancer	0.000385	0.00857	CbGeAlD
Methotrexate—GGH—female reproductive system—skin cancer	0.000375	0.00835	CbGeAlD
Methotrexate—ABCC1—hair follicle—skin cancer	0.000369	0.00819	CbGeAlD
Methotrexate—AOX1—nipple—skin cancer	0.000363	0.00807	CbGeAlD
Methotrexate—ABCC10—nipple—skin cancer	0.000353	0.00785	CbGeAlD
Methotrexate—FPGS—lymphoid tissue—skin cancer	0.000342	0.00761	CbGeAlD
Methotrexate—ATIC—lymphoid tissue—skin cancer	0.000331	0.00736	CbGeAlD
Methotrexate—FPGS—female reproductive system—skin cancer	0.00033	0.00734	CbGeAlD
Methotrexate—ATIC—female reproductive system—skin cancer	0.000319	0.0071	CbGeAlD
Methotrexate—SLC46A1—head—skin cancer	0.000319	0.00709	CbGeAlD
Methotrexate—GGH—head—skin cancer	0.000314	0.00697	CbGeAlD
Methotrexate—TYMS—connective tissue—skin cancer	0.000307	0.00682	CbGeAlD
Methotrexate—DHFR—connective tissue—skin cancer	0.000304	0.00676	CbGeAlD
Methotrexate—PGD—connective tissue—skin cancer	0.000292	0.0065	CbGeAlD
Methotrexate—SLC19A1—lymph node—skin cancer	0.00029	0.00644	CbGeAlD
Methotrexate—TYMS—skin of body—skin cancer	0.000277	0.00616	CbGeAlD
Methotrexate—FPGS—head—skin cancer	0.000276	0.00613	CbGeAlD
Methotrexate—SLCO3A1—mammalian vulva—skin cancer	0.000273	0.00606	CbGeAlD
Methotrexate—ATIC—head—skin cancer	0.000267	0.00593	CbGeAlD
Methotrexate—PGD—skin of body—skin cancer	0.000264	0.00586	CbGeAlD
Methotrexate—SLC16A1—epithelium—skin cancer	0.000259	0.00576	CbGeAlD
Methotrexate—SLC22A11—female reproductive system—skin cancer	0.000258	0.00573	CbGeAlD
Methotrexate—TYMS—mammalian vulva—skin cancer	0.000253	0.00562	CbGeAlD
Methotrexate—DHFR—mammalian vulva—skin cancer	0.00025	0.00556	CbGeAlD
Methotrexate—ABCC1—nipple—skin cancer	0.00025	0.00555	CbGeAlD
Methotrexate—MTHFR—lymphoid tissue—skin cancer	0.000246	0.00547	CbGeAlD
Methotrexate—PGD—mammalian vulva—skin cancer	0.000241	0.00535	CbGeAlD
Methotrexate—MTHFR—female reproductive system—skin cancer	0.000237	0.00527	CbGeAlD
Methotrexate—SLCO3A1—female reproductive system—skin cancer	0.000233	0.00519	CbGeAlD
Methotrexate—TYMS—lymphoid tissue—skin cancer	0.000224	0.00499	CbGeAlD
Methotrexate—SLC46A1—lymph node—skin cancer	0.000223	0.00496	CbGeAlD
Methotrexate—DHFR—lymphoid tissue—skin cancer	0.000222	0.00494	CbGeAlD
Methotrexate—SLCO1C1—head—skin cancer	0.000222	0.00493	CbGeAlD
Methotrexate—GGH—lymph node—skin cancer	0.00022	0.00488	CbGeAlD
Methotrexate—TYMS—female reproductive system—skin cancer	0.000216	0.00481	CbGeAlD
Methotrexate—DHFR—female reproductive system—skin cancer	0.000214	0.00476	CbGeAlD
Methotrexate—PGD—lymphoid tissue—skin cancer	0.000214	0.00475	CbGeAlD
Methotrexate—AOX1—mammalian vulva—skin cancer	0.000212	0.00471	CbGeAlD
Methotrexate—ABCC10—mammalian vulva—skin cancer	0.000206	0.00459	CbGeAlD
Methotrexate—PGD—female reproductive system—skin cancer	0.000206	0.00458	CbGeAlD
Methotrexate—MTHFR—head—skin cancer	0.000198	0.00441	CbGeAlD
Methotrexate—SLCO3A1—head—skin cancer	0.000195	0.00434	CbGeAlD
Methotrexate—FPGS—lymph node—skin cancer	0.000193	0.00429	CbGeAlD
Methotrexate—SLC16A1—female reproductive system—skin cancer	0.000192	0.00428	CbGeAlD
Methotrexate—SLCO1B1—female reproductive system—skin cancer	0.000187	0.00416	CbGeAlD
Methotrexate—ATIC—lymph node—skin cancer	0.000187	0.00415	CbGeAlD
Methotrexate—ABCC10—lymphoid tissue—skin cancer	0.000183	0.00407	CbGeAlD
Methotrexate—AOX1—female reproductive system—skin cancer	0.000182	0.00404	CbGeAlD
Methotrexate—TYMS—head—skin cancer	0.000181	0.00402	CbGeAlD
Methotrexate—DHFR—head—skin cancer	0.000179	0.00398	CbGeAlD
Methotrexate—ABCC3—female reproductive system—skin cancer	0.000178	0.00395	CbGeAlD
Methotrexate—ABCC10—female reproductive system—skin cancer	0.000177	0.00393	CbGeAlD
Methotrexate—PGD—head—skin cancer	0.000172	0.00383	CbGeAlD
Methotrexate—SLC16A1—head—skin cancer	0.000161	0.00357	CbGeAlD
Methotrexate—SLCO1C1—lymph node—skin cancer	0.000155	0.00345	CbGeAlD
Methotrexate—ABCC3—head—skin cancer	0.000148	0.0033	CbGeAlD
Methotrexate—ABCC4—female reproductive system—skin cancer	0.000147	0.00326	CbGeAlD
Methotrexate—ABCC1—mammalian vulva—skin cancer	0.000146	0.00324	CbGeAlD
Methotrexate—ABCC2—female reproductive system—skin cancer	0.000142	0.00315	CbGeAlD
Methotrexate—ABCB1—blood vessel—skin cancer	0.000141	0.00314	CbGeAlD
Methotrexate—MTHFR—lymph node—skin cancer	0.000139	0.00308	CbGeAlD
Methotrexate—SLCO3A1—lymph node—skin cancer	0.000137	0.00304	CbGeAlD
Methotrexate—SLCO1A2—head—skin cancer	0.000127	0.00283	CbGeAlD
Methotrexate—TYMS—lymph node—skin cancer	0.000127	0.00282	CbGeAlD
Methotrexate—DHFR—lymph node—skin cancer	0.000125	0.00279	CbGeAlD
Methotrexate—ABCC4—head—skin cancer	0.000122	0.00272	CbGeAlD
Methotrexate—SLC22A8—head—skin cancer	0.000121	0.0027	CbGeAlD
Methotrexate—ABCG2—mammalian vulva—skin cancer	0.000121	0.00269	CbGeAlD
Methotrexate—PGD—lymph node—skin cancer	0.000121	0.00268	CbGeAlD
Methotrexate—SLC16A1—lymph node—skin cancer	0.000113	0.0025	CbGeAlD
Methotrexate—AOX1—lymph node—skin cancer	0.000106	0.00236	CbGeAlD
Methotrexate—ABCC3—lymph node—skin cancer	0.000104	0.00231	CbGeAlD
Methotrexate—ABCC10—lymph node—skin cancer	0.000103	0.0023	CbGeAlD
Methotrexate—ALB—lymph node—skin cancer	8.86e-05	0.00197	CbGeAlD
Methotrexate—ABCC4—lymph node—skin cancer	8.57e-05	0.00191	CbGeAlD
Methotrexate—ABCC2—lymph node—skin cancer	8.3e-05	0.00184	CbGeAlD
Methotrexate—Visual impairment—Temozolomide—skin cancer	7.91e-05	0.000886	CcSEcCtD
Methotrexate—Erythema—Dactinomycin—skin cancer	7.9e-05	0.000885	CcSEcCtD
Methotrexate—Agranulocytosis—Fluorouracil—skin cancer	7.87e-05	0.00088	CcSEcCtD
Methotrexate—Ill-defined disorder—Bleomycin—skin cancer	7.86e-05	0.00088	CcSEcCtD
Methotrexate—Anaemia—Bleomycin—skin cancer	7.83e-05	0.000877	CcSEcCtD
Methotrexate—Diarrhoea—Vemurafenib—skin cancer	7.81e-05	0.000874	CcSEcCtD
Methotrexate—Erythema multiforme—Temozolomide—skin cancer	7.76e-05	0.000869	CcSEcCtD
Methotrexate—Urticaria—Imiquimod—skin cancer	7.73e-05	0.000866	CcSEcCtD
Methotrexate—Abdominal pain—Imiquimod—skin cancer	7.7e-05	0.000861	CcSEcCtD
Methotrexate—Body temperature increased—Imiquimod—skin cancer	7.7e-05	0.000861	CcSEcCtD
Methotrexate—Eye disorder—Temozolomide—skin cancer	7.67e-05	0.000859	CcSEcCtD
Methotrexate—Tinnitus—Temozolomide—skin cancer	7.66e-05	0.000857	CcSEcCtD
Methotrexate—Malaise—Bleomycin—skin cancer	7.64e-05	0.000855	CcSEcCtD
Methotrexate—Cardiac disorder—Temozolomide—skin cancer	7.62e-05	0.000853	CcSEcCtD
Methotrexate—Haemoglobin—Fluorouracil—skin cancer	7.6e-05	0.000851	CcSEcCtD
Methotrexate—Leukopenia—Bleomycin—skin cancer	7.59e-05	0.000849	CcSEcCtD
Methotrexate—Haemorrhage—Fluorouracil—skin cancer	7.57e-05	0.000847	CcSEcCtD
Methotrexate—Dizziness—Vemurafenib—skin cancer	7.55e-05	0.000845	CcSEcCtD
Methotrexate—Pharyngitis—Fluorouracil—skin cancer	7.51e-05	0.00084	CcSEcCtD
Methotrexate—Angiopathy—Temozolomide—skin cancer	7.45e-05	0.000834	CcSEcCtD
Methotrexate—Ataxia—Docetaxel—skin cancer	7.42e-05	0.000831	CcSEcCtD
Methotrexate—Immune system disorder—Temozolomide—skin cancer	7.42e-05	0.00083	CcSEcCtD
Methotrexate—Mediastinal disorder—Temozolomide—skin cancer	7.4e-05	0.000828	CcSEcCtD
Methotrexate—Cough—Bleomycin—skin cancer	7.4e-05	0.000828	CcSEcCtD
Methotrexate—Chills—Temozolomide—skin cancer	7.37e-05	0.000825	CcSEcCtD
Methotrexate—Ill-defined disorder—Dactinomycin—skin cancer	7.33e-05	0.000821	CcSEcCtD
Methotrexate—ABCC1—lymph node—skin cancer	7.31e-05	0.00163	CbGeAlD
Methotrexate—Anaemia—Dactinomycin—skin cancer	7.31e-05	0.000818	CcSEcCtD
Methotrexate—Liver function test abnormal—Docetaxel—skin cancer	7.29e-05	0.000816	CcSEcCtD
Methotrexate—Vomiting—Vemurafenib—skin cancer	7.26e-05	0.000812	CcSEcCtD
Methotrexate—Alopecia—Temozolomide—skin cancer	7.26e-05	0.000812	CcSEcCtD
Methotrexate—Chest pain—Bleomycin—skin cancer	7.21e-05	0.000808	CcSEcCtD
Methotrexate—Myalgia—Bleomycin—skin cancer	7.21e-05	0.000808	CcSEcCtD
Methotrexate—Rash—Vemurafenib—skin cancer	7.2e-05	0.000806	CcSEcCtD
Methotrexate—Mental disorder—Temozolomide—skin cancer	7.19e-05	0.000805	CcSEcCtD
Methotrexate—Dermatitis—Vemurafenib—skin cancer	7.19e-05	0.000805	CcSEcCtD
Methotrexate—Hypersensitivity—Imiquimod—skin cancer	7.17e-05	0.000803	CcSEcCtD
Methotrexate—Headache—Vemurafenib—skin cancer	7.15e-05	0.0008	CcSEcCtD
Methotrexate—Erythema—Temozolomide—skin cancer	7.15e-05	0.0008	CcSEcCtD
Methotrexate—Malnutrition—Temozolomide—skin cancer	7.15e-05	0.0008	CcSEcCtD
Methotrexate—Breast disorder—Docetaxel—skin cancer	7.13e-05	0.000798	CcSEcCtD
Methotrexate—Discomfort—Bleomycin—skin cancer	7.13e-05	0.000798	CcSEcCtD
Methotrexate—Malaise—Dactinomycin—skin cancer	7.13e-05	0.000798	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Docetaxel—skin cancer	7.11e-05	0.000796	CcSEcCtD
Methotrexate—Leukopenia—Dactinomycin—skin cancer	7.07e-05	0.000792	CcSEcCtD
Methotrexate—Dysgeusia—Temozolomide—skin cancer	7e-05	0.000784	CcSEcCtD
Methotrexate—Asthenia—Imiquimod—skin cancer	6.98e-05	0.000782	CcSEcCtD
Methotrexate—Confusional state—Bleomycin—skin cancer	6.97e-05	0.000781	CcSEcCtD
Methotrexate—Anaphylactic shock—Bleomycin—skin cancer	6.92e-05	0.000774	CcSEcCtD
Methotrexate—Back pain—Temozolomide—skin cancer	6.91e-05	0.000774	CcSEcCtD
Methotrexate—Pruritus—Imiquimod—skin cancer	6.89e-05	0.000771	CcSEcCtD
Methotrexate—Infection—Bleomycin—skin cancer	6.87e-05	0.000769	CcSEcCtD
Methotrexate—ABCB1—epithelium—skin cancer	6.87e-05	0.00153	CbGeAlD
Methotrexate—Nausea—Vemurafenib—skin cancer	6.78e-05	0.000759	CcSEcCtD
Methotrexate—Thrombocytopenia—Bleomycin—skin cancer	6.77e-05	0.000758	CcSEcCtD
Methotrexate—Vision blurred—Temozolomide—skin cancer	6.74e-05	0.000754	CcSEcCtD
Methotrexate—Myalgia—Dactinomycin—skin cancer	6.73e-05	0.000753	CcSEcCtD
Methotrexate—Alopecia—Fluorouracil—skin cancer	6.69e-05	0.000748	CcSEcCtD
Methotrexate—Diarrhoea—Imiquimod—skin cancer	6.66e-05	0.000746	CcSEcCtD
Methotrexate—Discomfort—Dactinomycin—skin cancer	6.65e-05	0.000744	CcSEcCtD
Methotrexate—Ill-defined disorder—Temozolomide—skin cancer	6.63e-05	0.000742	CcSEcCtD
Methotrexate—Anaemia—Temozolomide—skin cancer	6.61e-05	0.00074	CcSEcCtD
Methotrexate—Anorexia—Bleomycin—skin cancer	6.59e-05	0.000738	CcSEcCtD
Methotrexate—Erythema—Fluorouracil—skin cancer	6.59e-05	0.000737	CcSEcCtD
Methotrexate—Pancytopenia—Docetaxel—skin cancer	6.48e-05	0.000725	CcSEcCtD
Methotrexate—Hypotension—Bleomycin—skin cancer	6.46e-05	0.000723	CcSEcCtD
Methotrexate—Malaise—Temozolomide—skin cancer	6.45e-05	0.000722	CcSEcCtD
Methotrexate—Dizziness—Imiquimod—skin cancer	6.44e-05	0.000721	CcSEcCtD
Methotrexate—Vertigo—Temozolomide—skin cancer	6.42e-05	0.000719	CcSEcCtD
Methotrexate—Infection—Dactinomycin—skin cancer	6.41e-05	0.000717	CcSEcCtD
Methotrexate—Leukopenia—Temozolomide—skin cancer	6.4e-05	0.000716	CcSEcCtD
Methotrexate—Neutropenia—Docetaxel—skin cancer	6.38e-05	0.000714	CcSEcCtD
Methotrexate—Thrombocytopenia—Dactinomycin—skin cancer	6.32e-05	0.000707	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Bleomycin—skin cancer	6.3e-05	0.000705	CcSEcCtD
Methotrexate—Cough—Temozolomide—skin cancer	6.24e-05	0.000698	CcSEcCtD
Methotrexate—Paraesthesia—Bleomycin—skin cancer	6.21e-05	0.000695	CcSEcCtD
Methotrexate—Vision blurred—Fluorouracil—skin cancer	6.21e-05	0.000695	CcSEcCtD
Methotrexate—Convulsion—Temozolomide—skin cancer	6.19e-05	0.000693	CcSEcCtD
Methotrexate—Vomiting—Imiquimod—skin cancer	6.19e-05	0.000693	CcSEcCtD
Methotrexate—Dyspnoea—Bleomycin—skin cancer	6.17e-05	0.00069	CcSEcCtD
Methotrexate—Anorexia—Dactinomycin—skin cancer	6.15e-05	0.000688	CcSEcCtD
Methotrexate—Rash—Imiquimod—skin cancer	6.14e-05	0.000687	CcSEcCtD
Methotrexate—Dermatitis—Imiquimod—skin cancer	6.13e-05	0.000686	CcSEcCtD
Methotrexate—Pneumonia—Docetaxel—skin cancer	6.12e-05	0.000685	CcSEcCtD
Methotrexate—Headache—Imiquimod—skin cancer	6.1e-05	0.000683	CcSEcCtD
Methotrexate—Anaemia—Fluorouracil—skin cancer	6.09e-05	0.000681	CcSEcCtD
Methotrexate—Myalgia—Temozolomide—skin cancer	6.09e-05	0.000681	CcSEcCtD
Methotrexate—Arthralgia—Temozolomide—skin cancer	6.09e-05	0.000681	CcSEcCtD
Methotrexate—Infestation—Docetaxel—skin cancer	6.08e-05	0.000681	CcSEcCtD
Methotrexate—Infestation NOS—Docetaxel—skin cancer	6.08e-05	0.000681	CcSEcCtD
Methotrexate—ABCG2—lymph node—skin cancer	6.05e-05	0.00135	CbGeAlD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	6.04e-05	0.000676	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Docetaxel—skin cancer	6.03e-05	0.000675	CcSEcCtD
Methotrexate—Discomfort—Temozolomide—skin cancer	6.01e-05	0.000673	CcSEcCtD
Methotrexate—Decreased appetite—Bleomycin—skin cancer	6.01e-05	0.000673	CcSEcCtD
Methotrexate—Renal failure—Docetaxel—skin cancer	5.98e-05	0.000669	CcSEcCtD
Methotrexate—ABCB1—mammalian vulva—skin cancer	5.96e-05	0.00132	CbGeAlD
Methotrexate—Stomatitis—Docetaxel—skin cancer	5.93e-05	0.000664	CcSEcCtD
Methotrexate—Pain—Bleomycin—skin cancer	5.91e-05	0.000662	CcSEcCtD
Methotrexate—Conjunctivitis—Docetaxel—skin cancer	5.91e-05	0.000662	CcSEcCtD
Methotrexate—Leukopenia—Fluorouracil—skin cancer	5.9e-05	0.00066	CcSEcCtD
Methotrexate—Confusional state—Temozolomide—skin cancer	5.88e-05	0.000658	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Dactinomycin—skin cancer	5.88e-05	0.000658	CcSEcCtD
Methotrexate—Anaphylactic shock—Temozolomide—skin cancer	5.83e-05	0.000653	CcSEcCtD
Methotrexate—Infection—Temozolomide—skin cancer	5.8e-05	0.000649	CcSEcCtD
Methotrexate—Nausea—Imiquimod—skin cancer	5.78e-05	0.000647	CcSEcCtD
Methotrexate—Hepatobiliary disease—Docetaxel—skin cancer	5.75e-05	0.000644	CcSEcCtD
Methotrexate—Epistaxis—Docetaxel—skin cancer	5.74e-05	0.000642	CcSEcCtD
Methotrexate—Nervous system disorder—Temozolomide—skin cancer	5.72e-05	0.00064	CcSEcCtD
Methotrexate—Thrombocytopenia—Temozolomide—skin cancer	5.71e-05	0.000639	CcSEcCtD
Methotrexate—Convulsion—Fluorouracil—skin cancer	5.71e-05	0.000639	CcSEcCtD
Methotrexate—Feeling abnormal—Bleomycin—skin cancer	5.7e-05	0.000638	CcSEcCtD
Methotrexate—Agranulocytosis—Docetaxel—skin cancer	5.68e-05	0.000635	CcSEcCtD
Methotrexate—Skin disorder—Temozolomide—skin cancer	5.67e-05	0.000634	CcSEcCtD
Methotrexate—Hyperhidrosis—Temozolomide—skin cancer	5.64e-05	0.000631	CcSEcCtD
Methotrexate—Chest pain—Fluorouracil—skin cancer	5.61e-05	0.000628	CcSEcCtD
Methotrexate—Myalgia—Fluorouracil—skin cancer	5.61e-05	0.000628	CcSEcCtD
Methotrexate—Decreased appetite—Dactinomycin—skin cancer	5.61e-05	0.000628	CcSEcCtD
Methotrexate—Fatigue—Dactinomycin—skin cancer	5.56e-05	0.000622	CcSEcCtD
Methotrexate—Anorexia—Temozolomide—skin cancer	5.56e-05	0.000622	CcSEcCtD
Methotrexate—Discomfort—Fluorouracil—skin cancer	5.54e-05	0.00062	CcSEcCtD
Methotrexate—Pain—Dactinomycin—skin cancer	5.52e-05	0.000617	CcSEcCtD
Methotrexate—Urticaria—Bleomycin—skin cancer	5.49e-05	0.000615	CcSEcCtD
Methotrexate—Haemoglobin—Docetaxel—skin cancer	5.49e-05	0.000614	CcSEcCtD
Methotrexate—Body temperature increased—Bleomycin—skin cancer	5.47e-05	0.000612	CcSEcCtD
Methotrexate—Haemorrhage—Docetaxel—skin cancer	5.46e-05	0.000611	CcSEcCtD
Methotrexate—Hepatitis—Docetaxel—skin cancer	5.46e-05	0.000611	CcSEcCtD
Methotrexate—Confusional state—Fluorouracil—skin cancer	5.42e-05	0.000607	CcSEcCtD
Methotrexate—Pharyngitis—Docetaxel—skin cancer	5.42e-05	0.000607	CcSEcCtD
Methotrexate—Urinary tract disorder—Docetaxel—skin cancer	5.39e-05	0.000604	CcSEcCtD
Methotrexate—Anaphylactic shock—Fluorouracil—skin cancer	5.38e-05	0.000602	CcSEcCtD
Methotrexate—Urethral disorder—Docetaxel—skin cancer	5.35e-05	0.000599	CcSEcCtD
Methotrexate—Infection—Fluorouracil—skin cancer	5.34e-05	0.000598	CcSEcCtD
Methotrexate—Feeling abnormal—Dactinomycin—skin cancer	5.32e-05	0.000595	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Temozolomide—skin cancer	5.32e-05	0.000595	CcSEcCtD
Methotrexate—ABCB1—lymphoid tissue—skin cancer	5.29e-05	0.00118	CbGeAlD
Methotrexate—Insomnia—Temozolomide—skin cancer	5.28e-05	0.000591	CcSEcCtD
Methotrexate—Gastrointestinal pain—Dactinomycin—skin cancer	5.27e-05	0.00059	CcSEcCtD
Methotrexate—Nervous system disorder—Fluorouracil—skin cancer	5.27e-05	0.00059	CcSEcCtD
Methotrexate—Thrombocytopenia—Fluorouracil—skin cancer	5.26e-05	0.000589	CcSEcCtD
Methotrexate—Visual impairment—Docetaxel—skin cancer	5.26e-05	0.000589	CcSEcCtD
Methotrexate—Paraesthesia—Temozolomide—skin cancer	5.24e-05	0.000586	CcSEcCtD
Methotrexate—Dyspnoea—Temozolomide—skin cancer	5.2e-05	0.000582	CcSEcCtD
Methotrexate—Somnolence—Temozolomide—skin cancer	5.19e-05	0.000581	CcSEcCtD
Methotrexate—Erythema multiforme—Docetaxel—skin cancer	5.16e-05	0.000578	CcSEcCtD
Methotrexate—Dyspepsia—Temozolomide—skin cancer	5.14e-05	0.000575	CcSEcCtD
Methotrexate—Anorexia—Fluorouracil—skin cancer	5.12e-05	0.000573	CcSEcCtD
Methotrexate—Eye disorder—Docetaxel—skin cancer	5.1e-05	0.000571	CcSEcCtD
Methotrexate—ABCB1—female reproductive system—skin cancer	5.1e-05	0.00113	CbGeAlD
Methotrexate—Body temperature increased—Dactinomycin—skin cancer	5.1e-05	0.000571	CcSEcCtD
Methotrexate—Abdominal pain—Dactinomycin—skin cancer	5.1e-05	0.000571	CcSEcCtD
Methotrexate—Hypersensitivity—Bleomycin—skin cancer	5.1e-05	0.00057	CcSEcCtD
Methotrexate—Decreased appetite—Temozolomide—skin cancer	5.07e-05	0.000568	CcSEcCtD
Methotrexate—Cardiac disorder—Docetaxel—skin cancer	5.07e-05	0.000567	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Temozolomide—skin cancer	5.04e-05	0.000564	CcSEcCtD
Methotrexate—Fatigue—Temozolomide—skin cancer	5.03e-05	0.000563	CcSEcCtD
Methotrexate—Hypotension—Fluorouracil—skin cancer	5.02e-05	0.000562	CcSEcCtD
Methotrexate—Pain—Temozolomide—skin cancer	4.99e-05	0.000558	CcSEcCtD
Methotrexate—Asthenia—Bleomycin—skin cancer	4.96e-05	0.000555	CcSEcCtD
Methotrexate—Angiopathy—Docetaxel—skin cancer	4.95e-05	0.000555	CcSEcCtD
Methotrexate—Immune system disorder—Docetaxel—skin cancer	4.93e-05	0.000552	CcSEcCtD
Methotrexate—Mediastinal disorder—Docetaxel—skin cancer	4.92e-05	0.000551	CcSEcCtD
Methotrexate—Chills—Docetaxel—skin cancer	4.9e-05	0.000548	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Fluorouracil—skin cancer	4.9e-05	0.000548	CcSEcCtD
Methotrexate—Pruritus—Bleomycin—skin cancer	4.89e-05	0.000548	CcSEcCtD
Methotrexate—Insomnia—Fluorouracil—skin cancer	4.86e-05	0.000544	CcSEcCtD
Methotrexate—Paraesthesia—Fluorouracil—skin cancer	4.83e-05	0.00054	CcSEcCtD
Methotrexate—Alopecia—Docetaxel—skin cancer	4.83e-05	0.00054	CcSEcCtD
Methotrexate—Feeling abnormal—Temozolomide—skin cancer	4.81e-05	0.000538	CcSEcCtD
Methotrexate—Dyspnoea—Fluorouracil—skin cancer	4.79e-05	0.000536	CcSEcCtD
Methotrexate—Mental disorder—Docetaxel—skin cancer	4.78e-05	0.000535	CcSEcCtD
Methotrexate—Somnolence—Fluorouracil—skin cancer	4.78e-05	0.000535	CcSEcCtD
Methotrexate—Gastrointestinal pain—Temozolomide—skin cancer	4.77e-05	0.000534	CcSEcCtD
Methotrexate—Erythema—Docetaxel—skin cancer	4.75e-05	0.000532	CcSEcCtD
Methotrexate—Malnutrition—Docetaxel—skin cancer	4.75e-05	0.000532	CcSEcCtD
Methotrexate—Hypersensitivity—Dactinomycin—skin cancer	4.75e-05	0.000532	CcSEcCtD
Methotrexate—Dyspepsia—Fluorouracil—skin cancer	4.73e-05	0.00053	CcSEcCtD
Methotrexate—Decreased appetite—Fluorouracil—skin cancer	4.67e-05	0.000523	CcSEcCtD
Methotrexate—Dysgeusia—Docetaxel—skin cancer	4.66e-05	0.000521	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Fluorouracil—skin cancer	4.64e-05	0.000519	CcSEcCtD
Methotrexate—Urticaria—Temozolomide—skin cancer	4.63e-05	0.000519	CcSEcCtD
Methotrexate—Asthenia—Dactinomycin—skin cancer	4.63e-05	0.000518	CcSEcCtD
Methotrexate—Abdominal pain—Temozolomide—skin cancer	4.61e-05	0.000516	CcSEcCtD
Methotrexate—Body temperature increased—Temozolomide—skin cancer	4.61e-05	0.000516	CcSEcCtD
Methotrexate—Back pain—Docetaxel—skin cancer	4.6e-05	0.000515	CcSEcCtD
Methotrexate—Pain—Fluorouracil—skin cancer	4.6e-05	0.000514	CcSEcCtD
Methotrexate—Feeling abnormal—Fluorouracil—skin cancer	4.43e-05	0.000496	CcSEcCtD
Methotrexate—Diarrhoea—Dactinomycin—skin cancer	4.41e-05	0.000494	CcSEcCtD
Methotrexate—Vomiting—Bleomycin—skin cancer	4.4e-05	0.000492	CcSEcCtD
Methotrexate—Anaemia—Docetaxel—skin cancer	4.39e-05	0.000492	CcSEcCtD
Methotrexate—Rash—Bleomycin—skin cancer	4.36e-05	0.000488	CcSEcCtD
Methotrexate—Dermatitis—Bleomycin—skin cancer	4.36e-05	0.000488	CcSEcCtD
Methotrexate—Hypersensitivity—Temozolomide—skin cancer	4.3e-05	0.000481	CcSEcCtD
Methotrexate—Urticaria—Fluorouracil—skin cancer	4.27e-05	0.000478	CcSEcCtD
Methotrexate—ABCB1—head—skin cancer	4.26e-05	0.000947	CbGeAlD
Methotrexate—Leukopenia—Docetaxel—skin cancer	4.26e-05	0.000476	CcSEcCtD
Methotrexate—Body temperature increased—Fluorouracil—skin cancer	4.25e-05	0.000476	CcSEcCtD
Methotrexate—SLC19A1—Metabolism—ENO2—skin cancer	4.22e-05	0.002	CbGpPWpGaD
Methotrexate—Asthenia—Temozolomide—skin cancer	4.19e-05	0.000469	CcSEcCtD
Methotrexate—Cough—Docetaxel—skin cancer	4.15e-05	0.000464	CcSEcCtD
Methotrexate—Pruritus—Temozolomide—skin cancer	4.13e-05	0.000462	CcSEcCtD
Methotrexate—Convulsion—Docetaxel—skin cancer	4.12e-05	0.000461	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—CSPG4—skin cancer	4.11e-05	0.00194	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—FOXO4—skin cancer	4.11e-05	0.00194	CbGpPWpGaD
Methotrexate—Nausea—Bleomycin—skin cancer	4.11e-05	0.00046	CcSEcCtD
Methotrexate—Vomiting—Dactinomycin—skin cancer	4.1e-05	0.000459	CcSEcCtD
Methotrexate—Rash—Dactinomycin—skin cancer	4.07e-05	0.000455	CcSEcCtD
Methotrexate—Arthralgia—Docetaxel—skin cancer	4.05e-05	0.000453	CcSEcCtD
Methotrexate—Myalgia—Docetaxel—skin cancer	4.05e-05	0.000453	CcSEcCtD
Methotrexate—Chest pain—Docetaxel—skin cancer	4.05e-05	0.000453	CcSEcCtD
Methotrexate—MTHFR—Folate Metabolism—IL6—skin cancer	4.03e-05	0.0019	CbGpPWpGaD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	4.02e-05	0.00045	CcSEcCtD
Methotrexate—ABCC3—Transmembrane transport of small molecules—SLC12A2—skin cancer	4e-05	0.00189	CbGpPWpGaD
Methotrexate—Diarrhoea—Temozolomide—skin cancer	3.99e-05	0.000447	CcSEcCtD
Methotrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—skin cancer	3.97e-05	0.00187	CbGpPWpGaD
Methotrexate—Hypersensitivity—Fluorouracil—skin cancer	3.96e-05	0.000443	CcSEcCtD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.92e-05	0.00185	CbGpPWpGaD
Methotrexate—Confusional state—Docetaxel—skin cancer	3.91e-05	0.000438	CcSEcCtD
Methotrexate—DHFR—Folate Metabolism—TP53—skin cancer	3.91e-05	0.00185	CbGpPWpGaD
Methotrexate—Anaphylactic shock—Docetaxel—skin cancer	3.88e-05	0.000434	CcSEcCtD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	3.87e-05	0.00183	CbGpPWpGaD
Methotrexate—Dizziness—Temozolomide—skin cancer	3.86e-05	0.000432	CcSEcCtD
Methotrexate—Infection—Docetaxel—skin cancer	3.85e-05	0.000431	CcSEcCtD
Methotrexate—Nausea—Dactinomycin—skin cancer	3.83e-05	0.000429	CcSEcCtD
Methotrexate—Nervous system disorder—Docetaxel—skin cancer	3.8e-05	0.000426	CcSEcCtD
Methotrexate—Pruritus—Fluorouracil—skin cancer	3.8e-05	0.000426	CcSEcCtD
Methotrexate—Thrombocytopenia—Docetaxel—skin cancer	3.8e-05	0.000425	CcSEcCtD
Methotrexate—Skin disorder—Docetaxel—skin cancer	3.77e-05	0.000422	CcSEcCtD
Methotrexate—PGD—Metabolism—CSPG4—skin cancer	3.76e-05	0.00178	CbGpPWpGaD
Methotrexate—ABCC4—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.76e-05	0.00178	CbGpPWpGaD
Methotrexate—Vomiting—Temozolomide—skin cancer	3.71e-05	0.000415	CcSEcCtD
Methotrexate—Anorexia—Docetaxel—skin cancer	3.7e-05	0.000414	CcSEcCtD
Methotrexate—Rash—Temozolomide—skin cancer	3.68e-05	0.000412	CcSEcCtD
Methotrexate—Diarrhoea—Fluorouracil—skin cancer	3.68e-05	0.000412	CcSEcCtD
Methotrexate—Dermatitis—Temozolomide—skin cancer	3.68e-05	0.000411	CcSEcCtD
Methotrexate—Headache—Temozolomide—skin cancer	3.65e-05	0.000409	CcSEcCtD
Methotrexate—Hypotension—Docetaxel—skin cancer	3.63e-05	0.000406	CcSEcCtD
Methotrexate—FPGS—Metabolism—ENO2—skin cancer	3.59e-05	0.0017	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—ENO2—skin cancer	3.59e-05	0.0017	CbGpPWpGaD
Methotrexate—DHFR—Folate Metabolism—IL6—skin cancer	3.58e-05	0.00169	CbGpPWpGaD
Methotrexate—Dizziness—Fluorouracil—skin cancer	3.55e-05	0.000398	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Docetaxel—skin cancer	3.53e-05	0.000396	CcSEcCtD
Methotrexate—Insomnia—Docetaxel—skin cancer	3.51e-05	0.000393	CcSEcCtD
Methotrexate—FPGS—Disease—FOXO4—skin cancer	3.49e-05	0.00165	CbGpPWpGaD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.48e-05	0.00165	CbGpPWpGaD
Methotrexate—Paraesthesia—Docetaxel—skin cancer	3.48e-05	0.00039	CcSEcCtD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	3.48e-05	0.00164	CbGpPWpGaD
Methotrexate—Nausea—Temozolomide—skin cancer	3.47e-05	0.000388	CcSEcCtD
Methotrexate—TYMS—Mitotic G1-G1/S phases—CDKN2A—skin cancer	3.46e-05	0.00163	CbGpPWpGaD
Methotrexate—Dyspnoea—Docetaxel—skin cancer	3.46e-05	0.000387	CcSEcCtD
Methotrexate—Somnolence—Docetaxel—skin cancer	3.45e-05	0.000386	CcSEcCtD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	3.43e-05	0.00162	CbGpPWpGaD
Methotrexate—Vomiting—Fluorouracil—skin cancer	3.42e-05	0.000383	CcSEcCtD
Methotrexate—Dyspepsia—Docetaxel—skin cancer	3.42e-05	0.000382	CcSEcCtD
Methotrexate—ABCG2—Fluoropyrimidine Activity—TP53—skin cancer	3.39e-05	0.0016	CbGpPWpGaD
Methotrexate—Rash—Fluorouracil—skin cancer	3.39e-05	0.000379	CcSEcCtD
Methotrexate—Dermatitis—Fluorouracil—skin cancer	3.39e-05	0.000379	CcSEcCtD
Methotrexate—Decreased appetite—Docetaxel—skin cancer	3.37e-05	0.000377	CcSEcCtD
Methotrexate—Headache—Fluorouracil—skin cancer	3.37e-05	0.000377	CcSEcCtD
Methotrexate—SLC16A1—Cell surface interactions at the vascular wall—NRAS—skin cancer	3.37e-05	0.00159	CbGpPWpGaD
Methotrexate—ALB—SLC-mediated transmembrane transport—SLC12A2—skin cancer	3.35e-05	0.00158	CbGpPWpGaD
Methotrexate—Gastrointestinal disorder—Docetaxel—skin cancer	3.35e-05	0.000375	CcSEcCtD
Methotrexate—DHFR—Cell Cycle—MLH1—skin cancer	3.35e-05	0.00158	CbGpPWpGaD
Methotrexate—Fatigue—Docetaxel—skin cancer	3.35e-05	0.000374	CcSEcCtD
Methotrexate—SLC46A1—Disease—SHH—skin cancer	3.34e-05	0.00158	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—ENO2—skin cancer	3.34e-05	0.00158	CbGpPWpGaD
Methotrexate—Pain—Docetaxel—skin cancer	3.32e-05	0.000371	CcSEcCtD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	3.31e-05	0.00156	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—CDK4—skin cancer	3.29e-05	0.00156	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.28e-05	0.00155	CbGpPWpGaD
Methotrexate—MTHFR—Selenium Micronutrient Network—IL6—skin cancer	3.2e-05	0.00151	CbGpPWpGaD
Methotrexate—Feeling abnormal—Docetaxel—skin cancer	3.2e-05	0.000358	CcSEcCtD
Methotrexate—Nausea—Fluorouracil—skin cancer	3.19e-05	0.000357	CcSEcCtD
Methotrexate—Gastrointestinal pain—Docetaxel—skin cancer	3.17e-05	0.000355	CcSEcCtD
Methotrexate—ABCC2—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.17e-05	0.0015	CbGpPWpGaD
Methotrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—skin cancer	3.14e-05	0.00148	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.14e-05	0.00148	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PLIN2—skin cancer	3.08e-05	0.00146	CbGpPWpGaD
Methotrexate—Body temperature increased—Docetaxel—skin cancer	3.07e-05	0.000343	CcSEcCtD
Methotrexate—Abdominal pain—Docetaxel—skin cancer	3.07e-05	0.000343	CcSEcCtD
Methotrexate—PGD—Disease—SHH—skin cancer	3.05e-05	0.00144	CbGpPWpGaD
Methotrexate—PGD—Disease—ENO2—skin cancer	3.05e-05	0.00144	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PLIN2—skin cancer	3.01e-05	0.00142	CbGpPWpGaD
Methotrexate—ABCB1—lymph node—skin cancer	2.98e-05	0.000663	CbGeAlD
Methotrexate—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	2.98e-05	0.00141	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—SLC12A2—skin cancer	2.98e-05	0.00141	CbGpPWpGaD
Methotrexate—MTHFR—Disease—CSPG4—skin cancer	2.96e-05	0.0014	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—ERCC2—skin cancer	2.93e-05	0.00138	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—MLH1—skin cancer	2.92e-05	0.00138	CbGpPWpGaD
Methotrexate—SLC16A1—Cell surface interactions at the vascular wall—KRAS—skin cancer	2.9e-05	0.00137	CbGpPWpGaD
Methotrexate—AOX1—Disease—CSPG4—skin cancer	2.9e-05	0.00137	CbGpPWpGaD
Methotrexate—Hypersensitivity—Docetaxel—skin cancer	2.86e-05	0.00032	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—ENO2—skin cancer	2.8e-05	0.00132	CbGpPWpGaD
Methotrexate—Asthenia—Docetaxel—skin cancer	2.78e-05	0.000312	CcSEcCtD
Methotrexate—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	2.77e-05	0.00131	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	2.76e-05	0.0013	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—TERT—skin cancer	2.75e-05	0.0013	CbGpPWpGaD
Methotrexate—Pruritus—Docetaxel—skin cancer	2.74e-05	0.000307	CcSEcCtD
Methotrexate—DHFR—Metabolism—PLIN2—skin cancer	2.74e-05	0.00129	CbGpPWpGaD
Methotrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—skin cancer	2.74e-05	0.00129	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—FOXO4—skin cancer	2.72e-05	0.00129	CbGpPWpGaD
Methotrexate—Diarrhoea—Docetaxel—skin cancer	2.65e-05	0.000297	CcSEcCtD
Methotrexate—DHFR—Disease—CSPG4—skin cancer	2.63e-05	0.00124	CbGpPWpGaD
Methotrexate—Dizziness—Docetaxel—skin cancer	2.57e-05	0.000287	CcSEcCtD
Methotrexate—PGD—Metabolism—ENO2—skin cancer	2.56e-05	0.00121	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PLIN2—skin cancer	2.49e-05	0.00118	CbGpPWpGaD
Methotrexate—PGD—Disease—FOXO4—skin cancer	2.49e-05	0.00118	CbGpPWpGaD
Methotrexate—FPGS—Disease—ERCC2—skin cancer	2.49e-05	0.00118	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—CSPG4—skin cancer	2.48e-05	0.00117	CbGpPWpGaD
Methotrexate—Vomiting—Docetaxel—skin cancer	2.47e-05	0.000276	CcSEcCtD
Methotrexate—SLC16A1—Cell surface interactions at the vascular wall—HRAS—skin cancer	2.46e-05	0.00116	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—ERCC2—skin cancer	2.45e-05	0.00116	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.45e-05	0.00116	CbGpPWpGaD
Methotrexate—Rash—Docetaxel—skin cancer	2.45e-05	0.000274	CcSEcCtD
Methotrexate—Dermatitis—Docetaxel—skin cancer	2.44e-05	0.000274	CcSEcCtD
Methotrexate—Headache—Docetaxel—skin cancer	2.43e-05	0.000272	CcSEcCtD
Methotrexate—AOX1—Metabolism—CSPG4—skin cancer	2.43e-05	0.00115	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PLIN2—skin cancer	2.39e-05	0.00113	CbGpPWpGaD
Methotrexate—FPGS—Disease—TERT—skin cancer	2.33e-05	0.0011	CbGpPWpGaD
Methotrexate—Nausea—Docetaxel—skin cancer	2.3e-05	0.000258	CcSEcCtD
Methotrexate—DHFR—Metabolism—CSPG4—skin cancer	2.21e-05	0.00104	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PLIN2—skin cancer	2.19e-05	0.00104	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—BRAF—skin cancer	2.17e-05	0.00103	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	2.17e-05	0.00103	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—ERCC2—skin cancer	2.09e-05	0.000985	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—ERCC2—skin cancer	2.09e-05	0.000985	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	2.06e-05	0.000973	CbGpPWpGaD
Methotrexate—MTHFR—Disease—SHH—skin cancer	2.02e-05	0.000952	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ENO2—skin cancer	2.02e-05	0.000952	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—CSPG4—skin cancer	2.01e-05	0.000949	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PLIN2—skin cancer	1.98e-05	0.000934	CbGpPWpGaD
Methotrexate—AOX1—Disease—ENO2—skin cancer	1.97e-05	0.00093	CbGpPWpGaD
Methotrexate—AOX1—Disease—SHH—skin cancer	1.97e-05	0.00093	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—ERCC2—skin cancer	1.94e-05	0.000917	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—CSPG4—skin cancer	1.93e-05	0.00091	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CDK4—skin cancer	1.9e-05	0.000899	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TERT—skin cancer	1.9e-05	0.000898	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	1.89e-05	0.000892	CbGpPWpGaD
Methotrexate—FPGS—Disease—BRAF—skin cancer	1.85e-05	0.000873	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—TERT—skin cancer	1.82e-05	0.000859	CbGpPWpGaD
Methotrexate—DHFR—Disease—ENO2—skin cancer	1.79e-05	0.000846	CbGpPWpGaD
Methotrexate—DHFR—Disease—SHH—skin cancer	1.79e-05	0.000846	CbGpPWpGaD
Methotrexate—PGD—Disease—ERCC2—skin cancer	1.77e-05	0.000838	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CSPG4—skin cancer	1.77e-05	0.000834	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—PTGS2—skin cancer	1.76e-05	0.00083	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PLIN2—skin cancer	1.72e-05	0.000813	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.7e-05	0.000804	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CDK4—skin cancer	1.7e-05	0.000804	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—ENO2—skin cancer	1.69e-05	0.000797	CbGpPWpGaD
Methotrexate—PGD—Disease—TERT—skin cancer	1.66e-05	0.000786	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CDK4—skin cancer	1.66e-05	0.000784	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TERT—skin cancer	1.66e-05	0.000784	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ENO2—skin cancer	1.65e-05	0.000779	CbGpPWpGaD
Methotrexate—MTHFR—Disease—FOXO4—skin cancer	1.64e-05	0.000776	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.64e-05	0.000775	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—ERCC2—skin cancer	1.62e-05	0.000768	CbGpPWpGaD
Methotrexate—AOX1—Disease—FOXO4—skin cancer	1.6e-05	0.000758	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—PTGS2—skin cancer	1.6e-05	0.000758	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CSPG4—skin cancer	1.59e-05	0.000753	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PLIN2—skin cancer	1.55e-05	0.000732	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ENO2—skin cancer	1.5e-05	0.000709	CbGpPWpGaD
Methotrexate—FPGS—Disease—PTGS2—skin cancer	1.49e-05	0.000705	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	1.49e-05	0.000705	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CSPG4—skin cancer	1.49e-05	0.000704	CbGpPWpGaD
Methotrexate—PGD—Metabolism—ERCC2—skin cancer	1.49e-05	0.000702	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDK4—skin cancer	1.48e-05	0.000701	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PLIN2—skin cancer	1.47e-05	0.000696	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—PTGS2—skin cancer	1.47e-05	0.000695	CbGpPWpGaD
Methotrexate—DHFR—Disease—FOXO4—skin cancer	1.46e-05	0.00069	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.46e-05	0.000689	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—skin cancer	1.45e-05	0.000687	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—BRAF—skin cancer	1.44e-05	0.00068	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—TP53—skin cancer	1.4e-05	0.000662	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CSPG4—skin cancer	1.39e-05	0.000656	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—NRAS—skin cancer	1.37e-05	0.000646	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ENO2—skin cancer	1.37e-05	0.000645	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PLIN2—skin cancer	1.36e-05	0.000644	CbGpPWpGaD
Methotrexate—ALB—Vitamin B12 Metabolism—IL6—skin cancer	1.35e-05	0.000639	CbGpPWpGaD
Methotrexate—PGD—Disease—BRAF—skin cancer	1.32e-05	0.000622	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ENO2—skin cancer	1.31e-05	0.000618	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—CDKN2A—skin cancer	1.3e-05	0.000614	CbGpPWpGaD
Methotrexate—TYMS—Circadian rythm related genes—IL6—skin cancer	1.28e-05	0.000606	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—skin cancer	1.27e-05	0.0006	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—PTGS2—skin cancer	1.25e-05	0.000591	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—PTGS2—skin cancer	1.25e-05	0.000591	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CSPG4—skin cancer	1.25e-05	0.00059	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—TP53—skin cancer	1.2e-05	0.000568	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ENO2—skin cancer	1.2e-05	0.000567	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CSPG4—skin cancer	1.19e-05	0.000561	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—KRAS—skin cancer	1.18e-05	0.000556	CbGpPWpGaD
Methotrexate—MTHFR—Disease—ERCC2—skin cancer	1.17e-05	0.000553	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—PTGS2—skin cancer	1.16e-05	0.00055	CbGpPWpGaD
Methotrexate—FPGS—Disease—NRAS—skin cancer	1.16e-05	0.000549	CbGpPWpGaD
Methotrexate—AOX1—Disease—ERCC2—skin cancer	1.14e-05	0.00054	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—CDKN2A—skin cancer	1.13e-05	0.000536	CbGpPWpGaD
Methotrexate—ALB—Folate Metabolism—IL6—skin cancer	1.1e-05	0.00052	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CSPG4—skin cancer	1.1e-05	0.000519	CbGpPWpGaD
Methotrexate—MTHFR—Disease—TERT—skin cancer	1.1e-05	0.000518	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ENO2—skin cancer	1.08e-05	0.000512	CbGpPWpGaD
Methotrexate—AOX1—Disease—TERT—skin cancer	1.07e-05	0.000506	CbGpPWpGaD
Methotrexate—PGD—Disease—PTGS2—skin cancer	1.06e-05	0.000503	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.06e-05	0.0005	CbGpPWpGaD
Methotrexate—DHFR—Disease—ERCC2—skin cancer	1.04e-05	0.000491	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SHH—skin cancer	1.01e-05	0.000479	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ENO2—skin cancer	1.01e-05	0.000479	CbGpPWpGaD
Methotrexate—FPGS—Disease—KRAS—skin cancer	1e-05	0.000472	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—HRAS—skin cancer	1e-05	0.000472	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—ERCC2—skin cancer	9.8e-06	0.000463	CbGpPWpGaD
Methotrexate—DHFR—Disease—TERT—skin cancer	9.75e-06	0.000461	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PTGS2—skin cancer	9.74e-06	0.00046	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—ERCC2—skin cancer	9.58e-06	0.000452	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—IL6—skin cancer	9.57e-06	0.000452	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ENO2—skin cancer	9.43e-06	0.000446	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	9.39e-06	0.000444	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—NRAS—skin cancer	9.13e-06	0.000431	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—NRAS—skin cancer	9.05e-06	0.000428	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PTGS2—skin cancer	8.91e-06	0.000421	CbGpPWpGaD
Methotrexate—ALB—Selenium Micronutrient Network—IL6—skin cancer	8.74e-06	0.000413	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—ERCC2—skin cancer	8.71e-06	0.000412	CbGpPWpGaD
Methotrexate—MTHFR—Disease—BRAF—skin cancer	8.69e-06	0.000411	CbGpPWpGaD
Methotrexate—FPGS—Disease—HRAS—skin cancer	8.5e-06	0.000402	CbGpPWpGaD
Methotrexate—AOX1—Disease—BRAF—skin cancer	8.49e-06	0.000401	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ENO2—skin cancer	8.49e-06	0.000401	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.47e-06	0.0004	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PLIN2—skin cancer	8.41e-06	0.000397	CbGpPWpGaD
Methotrexate—PGD—Disease—NRAS—skin cancer	8.28e-06	0.000391	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FOXO4—skin cancer	8.26e-06	0.00039	CbGpPWpGaD
Methotrexate—FPGS—Disease—IL6—skin cancer	8.13e-06	0.000384	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ENO2—skin cancer	8.07e-06	0.000381	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—ERCC2—skin cancer	7.93e-06	0.000375	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—KRAS—skin cancer	7.86e-06	0.000371	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—KRAS—skin cancer	7.79e-06	0.000368	CbGpPWpGaD
Methotrexate—DHFR—Disease—BRAF—skin cancer	7.72e-06	0.000365	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—ERCC2—skin cancer	7.6e-06	0.000359	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	7.56e-06	0.000357	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ENO2—skin cancer	7.47e-06	0.000353	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	7.38e-06	0.000349	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PLIN2—skin cancer	7.37e-06	0.000348	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—TP53—skin cancer	7.24e-06	0.000342	CbGpPWpGaD
Methotrexate—PGD—Disease—KRAS—skin cancer	7.12e-06	0.000337	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTGS2—skin cancer	7.02e-06	0.000332	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—TP53—skin cancer	6.98e-06	0.00033	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ERCC2—skin cancer	6.97e-06	0.000329	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTGS2—skin cancer	6.86e-06	0.000324	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—NRAS—skin cancer	6.81e-06	0.000322	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CSPG4—skin cancer	6.78e-06	0.00032	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—HRAS—skin cancer	6.68e-06	0.000316	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.64e-06	0.000314	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—HRAS—skin cancer	6.62e-06	0.000313	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—IL6—skin cancer	6.34e-06	0.000299	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—TP53—skin cancer	6.31e-06	0.000298	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.31e-06	0.000298	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ERCC2—skin cancer	6.29e-06	0.000297	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—skin cancer	6.24e-06	0.000295	CbGpPWpGaD
Methotrexate—PGD—Disease—HRAS—skin cancer	6.06e-06	0.000286	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CSPG4—skin cancer	5.94e-06	0.000281	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERCC2—skin cancer	5.89e-06	0.000278	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—skin cancer	5.88e-06	0.000278	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—KRAS—skin cancer	5.86e-06	0.000277	CbGpPWpGaD
Methotrexate—PGD—Disease—IL6—skin cancer	5.8e-06	0.000274	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—skin cancer	5.74e-06	0.000271	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TERT—skin cancer	5.52e-06	0.000261	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ERCC2—skin cancer	5.48e-06	0.000259	CbGpPWpGaD
Methotrexate—MTHFR—Disease—NRAS—skin cancer	5.46e-06	0.000258	CbGpPWpGaD
Methotrexate—AOX1—Disease—NRAS—skin cancer	5.33e-06	0.000252	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—skin cancer	5.22e-06	0.000247	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—skin cancer	5.21e-06	0.000246	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	5.06e-06	0.000239	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—HRAS—skin cancer	4.98e-06	0.000235	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ERCC2—skin cancer	4.93e-06	0.000233	CbGpPWpGaD
Methotrexate—DHFR—Disease—NRAS—skin cancer	4.85e-06	0.000229	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—skin cancer	4.76e-06	0.000225	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—skin cancer	4.7e-06	0.000222	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ERCC2—skin cancer	4.69e-06	0.000221	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO2—skin cancer	4.61e-06	0.000218	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—skin cancer	4.59e-06	0.000217	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—skin cancer	4.56e-06	0.000215	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	4.5e-06	0.000213	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BRAF—skin cancer	4.37e-06	0.000206	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ERCC2—skin cancer	4.34e-06	0.000205	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—skin cancer	4.18e-06	0.000198	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—skin cancer	4.18e-06	0.000197	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO2—skin cancer	4.04e-06	0.000191	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—skin cancer	4e-06	0.000189	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—skin cancer	3.9e-06	0.000184	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—skin cancer	3.82e-06	0.000181	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—skin cancer	3.77e-06	0.000178	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—skin cancer	3.74e-06	0.000176	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.6e-06	0.00017	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—skin cancer	3.55e-06	0.000168	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—skin cancer	3.53e-06	0.000167	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—skin cancer	3.4e-06	0.000161	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—skin cancer	3.29e-06	0.000155	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NRAS—skin cancer	3.08e-06	0.000146	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—skin cancer	2.96e-06	0.00014	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—skin cancer	2.81e-06	0.000133	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRAS—skin cancer	2.75e-06	0.00013	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ERCC2—skin cancer	2.68e-06	0.000126	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—skin cancer	2.65e-06	0.000125	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—skin cancer	2.6e-06	0.000123	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—skin cancer	2.36e-06	0.000112	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—skin cancer	2.36e-06	0.000111	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ERCC2—skin cancer	2.35e-06	0.000111	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—skin cancer	2.25e-06	0.000106	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—skin cancer	2.01e-06	9.49e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—skin cancer	1.92e-06	9.09e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—skin cancer	1.61e-06	7.58e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—skin cancer	1.41e-06	6.64e-05	CbGpPWpGaD
